SIRT7 and breast carcinoma: In breast cancer cells, SIRT7 deacetylates H3K18 at the TIE2 promoter and suppresses its transcription, thereby inhibiting adriamycin-induced angiogenesis in breast cancer, as well as invasion and metastasis [13].